Safety and Feasibility of a Novel Split Design Left Atrial Appendage Occluder: From Preclinical Investigations to First‐in‐Human Application
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/1340277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 27.04.2026. Verfasst von Mingfei Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China, zs-hospital.sh.cn. Hauptthemen laut MEDLINE: Left Atrial Appendage Closure, Atrial Fibrillation, Atrial Appendage, Septal Occluder Device. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Clinical Research Center for Interventional Medicine.
Abstract (Originalsprache)
Objective
This study was designed to first evaluate the histological compatibility of the split occluder in preclinical animal models, followed by clinical validation of its procedural feasibility and occlusion effectiveness in a first‐in‐human trial cohort.
Methods
Eight healthy labrador retrievers were selected for this study. A split‐type occluder was introduced to occlude their left atrial appendage. The experimental animals were euthanized at 1, 3, and 6 months, respectively. Prior to being euthanized, transesophageal echocardiogram (TEE) and pulmonary vein computed tomography venography (CTV) were conducted on the subjects. A gross anatomical examination was then conducted on each animal post euthanasia. Additionally, data from 12 patients who underwent LAAO procedures using this device were included in the study. Each patient was monitored over a 3‐month follow‐up period.
Results
The operations to insert split left atrial appendage occluders into each of the eight test dogs were successful. Subsequent TEE and pulmonary vein CTV revealed that occluder surfaces exhibited no thrombus formation and that the occluders exhibited no significant residual flow. The gross anatomical examination indicated satisfactory endothelialization. The occluders were successfully implanted in all 12 patients, with no complications reported in the occlusions during the subsequent 3‐month follow‐up period.
Conclusions
In both animal and human studies, the split occluder demonstrated a significantly high immediate success rate in the occlusion of the left atrial appendage. This was accompanied by a low occurrence of residual shunts and device‐related complications, indicating its reliability and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China, zs-hospital.sh.cn.
- State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China, fudan.edu.cn.
- NHC Key Laboratory of Ischemic Heart Diseases, Shanghai, China.
- Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai, China, cacms.ac.cn.
- National Clinical Research Center for Interventional Medicine, Shanghai, China.
ORCID-Profile: Xiaochun Zhang, Daxin Zhou, Junbo Ge
Förderung
- Shanghai Clinical Research Center for Interventional Medicine
Zitieren
APA
Li, M., Lin, D., Zhang, L., Zhang, Y., Pan, W., Zhang, X., Zhou, D., & Ge, J. (2026). Safety and Feasibility of a Novel Split Design Left Atrial Appendage Occluder: From Preclinical Investigations to First‐in‐Human Application. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/1340277
Vancouver
Li M, Lin D, Zhang L, Zhang Y, Pan W, Zhang X, et al. Safety and Feasibility of a Novel Split Design Left Atrial Appendage Occluder: From Preclinical Investigations to First‐in‐Human Application. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/1340277
BibTeX
@article{Li2026,
author = {Li, Mingfei and Lin, Dawei and Zhang, Lei and Zhang, Yuan and Pan, Wenzhi and Zhang, Xiaochun and Zhou, Daxin and Ge, Junbo},
title = {Safety and Feasibility of a Novel Split Design Left Atrial Appendage Occluder: From Preclinical Investigations to First‐in‐Human Application},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/1340277}
}
EUVIMED